Ecuador Acute Myeloid Leukemia Drugs Market, By Sub-Type (M0 (Undifferentiated Acute Myelobastic Leukemia), M1 (Acute Myeloblastic Leukemia with Minimal Maturation), M2 (Acute Myeloblastic Leukemia with Maturation), M3 (Acute Promyelocytic Leukemia (APL)), M4 (Acute Myelomonocytic Leukemia), M5 (Acute Monocytic Leukemia), M6 (Acute Erythroid Leukemia), M7 (Acute Megakaryoblastic Leukemia), Drugs (Chemotherapy, Targeted Therapy, Immunotherapy), Drug Type (Branded and Generics), Route of Administration (Parenteral, Oral, and Others), Population Type (Geriatric, Adults, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029.
Ecuador Acute Myeloid Leukemia Drugs Market Analysis and Insights
Acute myeloid leukemia (AML) is a type of blood cancer that affects the bone marrow. In adults, it is the most frequent kind of acute leukemia. If left untreated, this type of cancer usually worsens swiftly. AML, also known as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a kind of leukemia that affects the blood cells.
Blood stem cells (immature cells) are produced in the bone marrow and over time they become mature. A blood stem cell can differentiate into a myeloid or lymphoid stem cell. A white blood cell develops from a lymphoid stem cell. A mature blood cell from a myeloid stem cell is one of three types that are red blood cells, granulocytes, and platelets.
The Ecuador acute myeloid leukemia drugs is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the Ecuador acute myeloid leukemia drugs market will grow at a CAGR of 4.5% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Forecast Period
|
2022 - 2029
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Thousand, Pricing in USD
|
|
Segments Covered
|
By Sub-Type (M0 (Undifferentiated Acute Myelobastic Leukemia), M1 (Acute Myeloblastic Leukemia with Minimal Maturation), M2 (Acute Myeloblastic Leukemia with Maturation), M3 (Acute Promyelocytic Leukemia (APL)), M4 (Acute Myelomonocytic Leukemia), M5 (Acute Monocytic Leukemia), M6 (Acute Erythroid Leukemia), M7 (Acute Megakaryoblastic Leukemia), Drugs (Chemotherapy, Targeted Therapy, Immunotherapy), Drug Type (Branded and Generics), Route of Administration (Parenteral, Oral, and Others), Population Type (Geriatric, Adults, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others),
|
|
Country Covered
|
Ecuador
|
|
Market Players Covered
|
Pfizer Inc., MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Novartis AG, Fresenius Kabi AG and F. Hoffmann-La Roche Ltd., among others
|
Ecuador Acute Myeloid Leukemia Drugs Market Dynamics
Drivers
- Rising Burden of Acute Myeloid Leukemia
The rising burden of cancer cases is one of the major boost of acute myeloid leukemia drugs. As increase in cancer cases leads to increase in demand for the treatment.
For instance,
- In Ecuador, the deaths attributed to cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p<0.001)
- Between the years 2003 and 2016, almost one fifth of deaths were attributed to cancer in Ecuador
From the above point we can conclude that the incidence of acute myeloid leukemia is increasing rapidly in Ecuador and Ecuador, as a result the market of acute myeloid leukemia drugs market is also increasing. The reason of increasing cancer cases can include several factors such as changing lifestyles and environmental changes, which are expected to further boost the market growth.
- Rising Clinical Trials and Product Approval
Rising clinical trials is one of the major driver points for the market. As more clinical trials will be done, chances of new drugs approval will increase.
For instance,
- In Ecuador, from 1995 to 2019, 1996 clinical trials were done and 23.5% of them are oncological trials
- The number of oncological trials is increasing over the years with different characteristics
From the above points we can established that oncological trials are increasing in Ecuador and Ecuador over the years which is expected to drive the growth of the acute myeloid leukemia drugs market.
Opportunities
- Strategic Initiatives By Market Players
The need for medications for treatment of acute myeloid leukemia in Ecuador and Ecuador has increased due to the rise in prevalence of acute myeloid leukemia, advanced therapies for treatment of leukemia and oncology being the largest therapeutic market with unmet medical needs. These factors enhance the necessity for chemotherapy and immunotherapy and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
For instance,
- In June 2020, AbbVie Inc., received the Food and Drug (FDA) approval for Venclexta (venetoclax), for the overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. Venclexta received approval, in combination with azacitidine, for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Approval was also granted in Mexico, Israel, Puerto Rico and Ecuador. The approval gained had ensured post marketing rights of venetoclax in Ecuador and its clinical use in cancer research hospitals, situated in Ecuador and Ecuador
- Rise Of Innovative Therapies
Relapse continues to be a major issue in providing cure in patients with acute myeloid leukemia (AML). The outcome after relapse is not uniform in all patients with AML and is dependent on several factors, such as age, genetic profile, cytogenetics at initial diagnosis, duration of first complete remissions. Hence, to overcome the hurdles, innovative therapies are required, with treatment strategies based on identification of specific targets and methods to overcome these aberrant processes.
For instance,
- In June 2021, Bristol Myers Squibb received the approval for Onureg (azacitidine tablets). Onureg is the first oral maintenance innovative therapy, for patients with a broad range of acute myeloid leukemia (AML) subtypes
The use of innovative therapies is expected to improve diagnosis, risk stratification, and disease monitoring of acute myeloid leukemia. The innovative combined drug therapies are expected to patient outcomes in the coming years. Hence, the use of innovative therapies is expected to create lucrative opportunity for the Ecuador and Ecuador acute myeloid leukemia drugs market.
Restraints/Challenges
However, high cost associated with the available and lack of infrastructure in low-income countries will impede the growth rate of Ecuador acute myeloid leukemia drugs market. Additionally, the risks incurred while using the orthotic devices will hinder the Ecuador acute myeloid leukemia drugs market growth. The adverse effects associated with cancer drugs and less expertise will further challenge the market in the forecast period mentioned above.
The Ecuador acute myeloid leukemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Ecuador acute myeloid leukemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Ecuador acute myeloid leukemia drugs is a chronic foot disorder that is relatively uncommon and whose incidence is unknown. The study by the Science Direct, states that the incidence of acute myeloid leukemia in Ecuador is 4.79 AML cases per 100,000 habitants, with the highest incidence rate observed in Piura (a coastal city in Northern Ecuador) with 38 AML cases per 100,000 habitants.
Ecuador acute myeloid leukemia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on the Ecuador Acute Myeloid Leukemia Drugs Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the chemotherapy medication adherence during the pandemic.
Recent Development
- In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Ecuador, thereby increasing the market growth
Ecuador Acute Myeloid Leukemia Drugs Market Scope
The Ecuador acute myeloid leukemia drugs market is segmented on the basis of sub-type, drugs, drug type, and route of administration, population type end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Sub-Type
- M3 (Acute Promyelocytic Leukemia (Apl))
- M2 (Acute Myeloblastic Leukemia With Maturation)
- M4 (Acute Myelomonocytic Leukemia)
- M0 (Undifferentiated Acute Myelobastic Leukemia)
- M1 (Acute Myeloblastic Leukemia With Minimal Maturation)
- M5 (Acute Monocytic Leukemia)
- M7 (Acute Megakaryoblastic Leukemia)
- M6 (Acute Erythroid Leukemia)
On the basis of sub-type, the Ecuador acute myeloid leukemia drugs market is segmented into M0 (undifferentiated acute myelobastic leukemia), M1 (Acute myeloblastic leukemia with minimal maturation), M2 (acute myeloblastic leukemia with maturation), M3 (acute promyelocytic leukemia (APL)), M4 (acute myelomonocytic leukemia), M5 (acute monocytic leukemia), M6 (acute erythroid leukemia), M7 (acute megakaryoblastic leukemia) and M6 (acute erythroid leukemia)
Drugs
- Chemotherapy
- Targeted Therapy
- Immunotherapy
On the basis of drugs, the Ecuador acute myeloid leukemia drugs market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. The chemotherapy is sub-segmented into cytosar, daunorubicin doxorubicin, methotrexate, decitabin, cladribine and others. The targeted therapy is sub segmented into venetoclax (venclexta), midostaurin (rydapt), enasidenib (idhifa) and others. The immunotherapy is sub-segmented into obinutuzumab (gazyva/gazyvaro), rituximab, interferons, alemtuzumab (campath) and others.
Drug Type
- Branded
- Generics
On the basis of drug type, the Ecuador acute myeloid leukemia drugs market is segmented into branded and generics. The branded segment is sub-segmented into cytosar, venclexta, rydapt, idhifa, gazyva/gazyvaro, campath and others.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the Ecuador acute myeloid leukemia drugs market is segmented into oral, parenteral and others. The oral segment is sub-segmented into tablet, capsule and others. The parenteral segment is further sub-segmented into subcutaneous, intravenous and others
Population Type
- Adult
- Geriatric
- Pediatric
On the basis of population type, the Ecuador acute myeloid leukemia drugs market is segmented into pediatric, adult and geriatric. The adults is sub-segmented into male and female.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Centers
- Others
On the basis of end user, the Ecuador acute myeloid leukemia drugs market is segmented into hospitals, specialty clinics, ambulatory centers and others.
Distribution Channel
- Direct Sales
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Ecuador acute myeloid leukemia drugs market is segmented into direct sales, hospital pharmacy, retail pharmacy, online pharmacy and others.
Pipeline Analysis (not provided)
- Cytarabine (Phase III)
- BI 836858 (Phase II)
- AZD5991, with Venetoclax (Phase II)
- AZD5991 (Phase I)
- CC-95251 (Phase I)
- Decitabine (Phase I)
- MK-0482 (Phase I)
Ecuador Acute Myeloid Leukemia Drugs Market Regional Analysis/Insights
The Ecuador acute myeloid leukemia drugs market is analyzed and market size insights and trends are provided by country, sub-type, drugs, drug type, and route of administration, population type, end user and distribution channel as referenced above.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Ecuador Acute Myeloid Leukemia Drugs Market Share Analysis
The Ecuador acute myeloid leukemia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Ecuador acute myeloid leukemia drugs market.
Some of the major players operating in the Ecuador acute myeloid leukemia drugs market are Pfizer Inc., MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Novartis AG, Fresenius Kabi AG and F. Hoffmann-La Roche Ltd., among others.
SKU-